隽泰控股2025中期报告

Interim Report中 期 報 告2025 Management Discussion and Analysis2Corporate Governance and Other Information11Interim Condensed Consolidated Statement of Profit or Loss andOther Comprehensive Income18Interim Condensed Consolidated Statement of Financial Position19Interim Condensed Consolidated Statement of Changes in Equity20Interim Condensed Consolidated Statement of Cash Flows21Notes to the Interim Condensed Consolidated Financial Statements22 Management Discussion and Analysis管理層討論及分析 RESULTS, BUSINESS REVIEW AND PROSPECTS Results (i)(ii)(iii)(iv) For the six months ended 30 June 2025, AMCO United Holding Limited(the“Company”)and its subsidiaries(collectively referred to as the“Group”) are principally engaged in (i) manufacture and sale of medicaldevices products (“Medical Products Business”); (ii) manufacture and saleof plastic moulding products (“Plastic Products Business”); (iii) provisionof money lending (“Money Lending Business”); and (iv) investment insecurities (“Securities Investment”). Duringthe period under review,revenue of the Group amounted toHK$27.1 million, representing an increase of HK$5.1 million or 23.2%fromHK$22.0 million for the corresponding period last year.Suchincrease was mainly attributable to the increase in revenue from theMedical Products Business. 27,100,00022,000,0005,100,00023.2% 8,400,0006,800,0001,600,00023.5%30.9%30.8% Gross profit of the Group was HK$8.4 million, representing an increaseofHK$1.6 million or 23.5%as compared to HK$6.8 million for thecorresponding period last year. Gross profit margin slightly increased to30.9% (30 June 2024: 30.8%). Other losses, net of other income and other gains, during the periodunderreview recorded profit of HK$3.4 million as compared to lossof HK$22.9 million in the corresponding period of 2024. The amountincluded realised and unrealised fair value gain/(loss) of held-for-tradinginvestments arising from Securities Investment and the change of fairvalue on financial liabilities at fair value through profit or loss in thecurrent period. 3,400,00022,900,000 Management Discussion and Analysis 3 0 0 , 0 0 02 , 5 0 0 , 0 0 02,200,000500,0006,400,0005,900,0008.5% Thedistribution costs increased by HK$0.3 million to HK$2.5 millionduringthe period under review(30 June 2024:HK$2.2 million),alongside with the increase in revenue of Medical Products Business. Theadministrative expenses increased by HK$0.5 million to HK$6.4 million(30 June 2024: HK$5.9 million), representing an increase of 8.5% overthe corresponding period last year. 1,800,0001,200,000 Financecosts amounted to HK$1.8 million(30 June 2024:HK$1.2million) for the period under review, which represented interest on bondpayables. 1,100,00025,400,000 As a result, the overall profit attributable to owners of the Company wasHK$1.1 million, which turnaround from loss of HK$25.4 million for thecorresponding period of 2024. Business Review Medical Products Business 22,100,00016,300,0005,800,00081.3% For the six months ended 30 June 2025, the revenue from the MedicalProducts Business increased by HK$5.8 million to HK$22.1 million, ascompared to revenue of HK$16.3 million recorded in the same periodlast year, which accounted for 81.3% of the Group’s total revenue forthe period under review. In the first half of 2025, the sales increasedprimarily attributable to the initial execution of the Group’s strategic planto expand service coverage and diversify its product portfolio within theMedical Products Business. Management Discussion and Analysis 管理層討論及分析 Segment profit of the Medical Products Business amounted to HK$3.3million for the six months ended 30 June 2025, as compared to segmentprofit of HK$1.7 million in the corresponding period last year. To copewith the challenge of fluctuating sales order, the Group is persisting todeploy business strategies of streamlining and outsourcing of businessprocesses,implementing strict cost control and ensuring effectiveutilisation of resources with an aim to maintain its long-term sustainablecompetitiveadvantages in the business segment.In the meantime,theGroup is actively exploring and identifying potential businessopportunities to expand its customer base and also the products andservicesportfolio of the business segment in order to generate andbroaden the income streams of the Medical Products Business. 3,300,0001,700,000 Money Lending Business For the six months ended 30 June 2025, the Group recorded loan interestincome of HK$5.1 million from its Money Lending Business, representinga decrease of HK$0.6 million or 10.5% as compared to HK$5.7 millionfor the corresponding period last year, which accounted for 18.7% ofthe Group’s total revenue for the period under review. Segment lossof the Money Lending Business amounted to HK$1.3 million (30 June2024: loss of HK$0.7 million). The outstanding principal and interestamount of loan receivables as at 30 June 2025 was HK$152.7 million(31December 2024:HK$149.6 million).The Group will